DK1229909T3 - Transdermal indgivelse af lasofoxifen - Google Patents

Transdermal indgivelse af lasofoxifen

Info

Publication number
DK1229909T3
DK1229909T3 DK01939751T DK01939751T DK1229909T3 DK 1229909 T3 DK1229909 T3 DK 1229909T3 DK 01939751 T DK01939751 T DK 01939751T DK 01939751 T DK01939751 T DK 01939751T DK 1229909 T3 DK1229909 T3 DK 1229909T3
Authority
DK
Denmark
Prior art keywords
devices
lasofoxifene
carrier vehicle
reservoir
drug
Prior art date
Application number
DK01939751T
Other languages
Danish (da)
English (en)
Inventor
David Fikstad
Danyi Quan
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1229909T3 publication Critical patent/DK1229909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01939751T 2000-06-01 2001-05-31 Transdermal indgivelse af lasofoxifen DK1229909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20878900P 2000-06-01 2000-06-01
PCT/US2001/017567 WO2001091724A2 (en) 2000-06-01 2001-05-31 Transdermal delivery of lasofoxifene

Publications (1)

Publication Number Publication Date
DK1229909T3 true DK1229909T3 (da) 2004-03-15

Family

ID=22776068

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01939751T DK1229909T3 (da) 2000-06-01 2001-05-31 Transdermal indgivelse af lasofoxifen

Country Status (24)

Country Link
US (1) US20020037311A1 (cg-RX-API-DMAC7.html)
EP (1) EP1229909B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003534368A (cg-RX-API-DMAC7.html)
KR (1) KR100795870B1 (cg-RX-API-DMAC7.html)
CN (1) CN1400897A (cg-RX-API-DMAC7.html)
AT (1) ATE253910T1 (cg-RX-API-DMAC7.html)
AU (2) AU785199B2 (cg-RX-API-DMAC7.html)
BR (1) BR0106680A (cg-RX-API-DMAC7.html)
CA (1) CA2380769A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2002488A3 (cg-RX-API-DMAC7.html)
DE (1) DE60101206T2 (cg-RX-API-DMAC7.html)
DK (1) DK1229909T3 (cg-RX-API-DMAC7.html)
ES (1) ES2210168T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052472A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202592A3 (cg-RX-API-DMAC7.html)
IL (2) IL147640A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02001152A (cg-RX-API-DMAC7.html)
NZ (1) NZ516582A (cg-RX-API-DMAC7.html)
PL (1) PL201222B1 (cg-RX-API-DMAC7.html)
PT (1) PT1229909E (cg-RX-API-DMAC7.html)
RU (1) RU2328276C2 (cg-RX-API-DMAC7.html)
TR (1) TR200400241T4 (cg-RX-API-DMAC7.html)
WO (1) WO2001091724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200519B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7564908B2 (en) * 2004-09-23 2009-07-21 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
US7804912B2 (en) * 2004-09-23 2010-09-28 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
EP2167001A4 (en) * 2007-07-10 2012-10-31 Agile Therapeutics Inc DEVICE FOR THE DERIVED ULTRASONIC WELDING
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
CN103751138A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN103830207A (zh) * 2014-03-14 2014-06-04 崔书豪 一种酒石酸拉索昔芬贴膏剂
KR20180035209A (ko) * 2015-07-24 2018-04-05 킴벌리-클라크 월드와이드, 인크. 종양에 대한 활성제의 더 나은 전달 방법
US10737082B2 (en) * 2015-07-24 2020-08-11 Sorrento Therapeutics, Inc. Methods for lymphatic delivery of active agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
CA2208132A1 (en) * 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Also Published As

Publication number Publication date
CZ2002488A3 (cs) 2002-06-12
RU2002105378A (ru) 2003-11-10
US20020037311A1 (en) 2002-03-28
IL147640A (en) 2007-03-08
PT1229909E (pt) 2004-04-30
PL201222B1 (pl) 2009-03-31
NZ516582A (en) 2004-08-27
PL354628A1 (en) 2004-02-09
IL147640A0 (en) 2002-08-14
WO2001091724A3 (en) 2002-05-30
DE60101206D1 (de) 2003-12-18
BR0106680A (pt) 2002-04-30
DE60101206T2 (de) 2004-09-02
ATE253910T1 (de) 2003-11-15
AU6523501A (en) 2001-12-11
KR100795870B1 (ko) 2008-01-21
MXPA02001152A (es) 2002-08-20
HK1052472A1 (zh) 2003-09-19
EP1229909B1 (en) 2003-11-12
HUP0202592A2 (hu) 2002-12-28
TR200400241T4 (tr) 2004-04-21
HUP0202592A3 (en) 2003-07-28
AU2007200426A1 (en) 2007-02-22
JP2003534368A (ja) 2003-11-18
WO2001091724A2 (en) 2001-12-06
KR20030025219A (ko) 2003-03-28
RU2328276C2 (ru) 2008-07-10
ZA200200519B (en) 2003-04-22
CN1400897A (zh) 2003-03-05
AU785199B2 (en) 2006-11-02
CA2380769A1 (en) 2001-12-06
EP1229909A2 (en) 2002-08-14
ES2210168T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
US10709669B2 (en) Microreservoir system based on polysiloxanes and ambiphilic solvents
DE60023520D1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
ES2733812T3 (es) Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos
WO2004052336A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
DE60101206D1 (de) Transdermale verabreichung von lasofoxifen
RU2003128642A (ru) Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона
DE69326461D1 (de) Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
US20010033858A1 (en) Transdermal drug patch
DK0812208T3 (da) Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer
AU3932600A (en) Transdermal drug delivery devices comprising a polyurethane drug reservoir
DE602005011653D1 (de) Medizinprodukt mit gewebeabhängiger arzneimittelelution
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
PT1047409E (pt) Tts contendo um antioxidante
TW200514590A (en) Hydrophilic adhesives for delivery of herbal medicines
TW200616589A (en) Transdermal delivery of drugs based on crystal size
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
US9056060B2 (en) Non-reactive adhesive useful in transdermal drug delivery system
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
ES2962896T3 (es) Parche que contiene rotigotina
NZ332746A (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
MY129063A (en) Transdermal delivery of lasofoxifene
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
WO2024189202A1 (en) Medical patch comprising capsaicin
CN118103036A (zh) 用于透皮施用替扎尼定的透皮治疗系统